Patients could instantly save up to $200 off the cost of their co-pay
CALIFON, NJ - February 1, 2011 - PediatRx Inc. (“PediatRx”) is
pleased to announce the launch of a co-pay assistance program* to support use of
GRANISOL.
This unique program allows patients to instantly save up to $200 off their co-pay
each time they are prescribed GRANISOL. There are various ways in which the program
can be accessed. A mobile phone texting version allows patients and caregivers to
text the word 'GRAN' or 'GRANI' to the number '55065' to enroll into the program
and, if they wish, into a prescription reminder service which quickly and easily
initiates an approved refill at the patients' preferred pharmacy. The co-pay assistance
program is also available via the PediatRx home page on-line at www.pediatrx.com.
The GRANISOL packaging also contains details for enrollment in this special program,
which is available at more than 60,000 U.S. pharmacies.
Jorge Rodriguez, PediatRx's Chief Commercial Officer said, "We are excited to be
able to bring GRANISOL to market as the first commercial entry for PediatRx. For
patients undergoing chemo- or radio-therapy who may be unsuitable for other modes
of administration of granisetron, or simply prefer an oral liquid anti-emetic, GRANISOL
may offer an alternative. From our market research and speaking to customers and
listening to some of their foremost concerns in this sector, it was clear that cost
of therapy can be a significant issue. PediatRx is conscious of both the emotional
and financial burden placed on patients fighting cancer. We are proud to be able
to offer this user-friendly, co-pay assistance program to help with access to GRANISOL
and, more importantly, potentially reduce the overall cost of therapy to the patient.
In addition, we are leveraging technology via mobile texting and the internet to
initiate prior approvals should the patient’s insurance company require it."
GRANISOL, used to prevent nausea and vomiting, is the only granisetron available
in the USA as an orange flavored, ready-to-use oral liquid solution. GRANISOL may
be dosed once or twice daily on the day of chemo- or radio-therapy and is packaged
in a 30mL bottle containing 2mg/10mL.
Customers are able to order GRANISOL (NDC number 52547-0801-30) through their usual
channels.
*Program is administered via a third-party provider. Medicaid and Medicare patients
are not eligible for enrollment.
About GRANISOL
Granisetron is indicated for the prevention of:
- Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin.
- Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation.
Selected Safety Information
- Granisetron is contraindicated in patients with known hypersensitivity to the drug or any of its components.
- QT prolongation has been reported with granisetron. Use of Granisol Oral Solution in patients concurrently treated with drugs known to prolong the QT interval and/or are arrhythmogenic may result in clinical consequences.
- This drug should be used during pregnancy only if clearly needed.
- It is not known whether granisetron is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when granisetron is administered to a nursing woman.
- Efficacy and safety were maintained with increasing age in the geriatric population.
- Safety and effectiveness in pediatric patients have not been established.
- The most common side effects observed with administration of granisetron were headache, asthenia, somnolence, diarrhea and constipation.
About PediatRx Inc.
PediatRx Inc. (www.pediatrx.com) is a unique
hospital specialty pharmaceutical company and the first to focus on children suffering
from serious conditions requiring hospitalization and hospital care. PediatRx trades
on the OTCBB under the ticker symbol PEDX.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements
are projections of events, revenues, income, future economic, research, development,
reformulation, product performance or management's plans and objectives for future
operations. In some cases you can identify forward-looking statements by the use
of terminology such as "may", "should", "anticipates", "believes", "expects", "intends",
"forecasts", "plans", "future", "strategy", or words of similar meaning. Forward-looking
statements in this press release include those concerning PediatRx’s intention to
acquire and/or license, and become the sole marketer in the United States, of other
FDA-approved, branded prescription drugs as well as reformulate certain compounds
as more appropriate forms. While these forward-looking statements and any assumptions
upon which they are based are made in good faith and reflect current judgment regarding
the direction of the business operations of PediatRx, actual results will almost
always vary, sometimes materially, from any estimates, predictions, projections,
assumptions or other future performance suggested in this press release. These statements
are predictions and involve known and unknown risks, uncertainties and other factors,
including the risk that PediatRx cannot execute its business plan for lack of capital
or other resources, distribution, partnering or licensing/acquisition opportunities,
as well as the risks described in the periodic disclosure documents filed on EDGAR
by PediatRx, copies of which are also available on the company’s website. Any of
these risks could cause PediatRx or its industry's actual results, levels of activity,
performance or achievements to be materially different from those expressed or implied
by the forward-looking statements in this press release. Except as required by applicable
law, including the securities laws of the United States, PediatRx does not intend
to update any of the forward-looking statements to conform these statements to actual
results.